Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masato Nakamura

Showing results (591-600 of 709) with videos related to

Pageof 71
Sort By:
JCO Precision Oncology|January 20, 2022
<i>RAS</i> Mutations in Circulating Tumor DNA and Clinical Outcomes of Rechallenge Treatment With Anti-EGFR Antibodies in Patients With Metastatic Colorectal CancerYu Sunakawa, Masato Nakamura, Masahiro Ishizaki, et al.
Diagnostics (Basel, Switzerland)|April 3, 2021
Percutaneous Two-Dimensional Shear Wave Elastography for Diagnosis of Pancreatic TumorYotaro Iino, Hitoshi Maruyama, Rintaro Mikata, et al.
Cancer Medicine|July 28, 2018
A prospective Phase II study to examine the relationship between quality of life and adverse events of first-line chemotherapy plus cetuximab in patients with KRAS wild-type unresectable metastatic colorectal cancer: QUACK trialShigeyoshi Iwamoto, Akira Ooki, Satoshi Morita, et al.
ESMO Open|August 2, 2017
S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT studyHideo Baba, Yasuhide Yamada, Daisuke Takahari, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 13, 2012
Using chimeric mice with humanized livers to predict human drug metabolism and a drug-drug interactionToshihiko Nishimura, Toshiko Nishimura, Yajing Hu, et al.
ESMO Open|May 2, 2018
Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancerMasahito Kotaka, Takeharu Yamanaka, Takayuki Yoshino, et al.
Nature Communications|November 25, 2024
Modified FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: a randomized phase II DEEPER trialManabu Shiozawa, Yu Sunakawa, Takanori Watanabe, et al.
Scientific Reports|July 17, 2023
Estimation of the effect of atezolizumab plus bevacizumab on pulmonary arterial hypertension using computed tomography in HCC patientsTakayuki Kondo, Kisako Fujiwara, Miyuki Nakagawa, et al.
Liver Cancer|June 24, 2026
Disease Complexity and Nodule-Specific Responses to Atezolizumab plus Bevacizumab in Advanced Hepatocellular CarcinomaSae Yumita, Sadahisa Ogasawara, Makoto Fujiya, et al.
Targeted Oncology|September 22, 2020
Early Tumor Shrinkage and Depth of Response in the Second-Line Treatment for KRAS exon2 Wild-Type Metastatic Colorectal Cancer: An Exploratory Analysis of the Randomized Phase 2 Trial Comparing Panitumumab and Bevacizumab in Combination with FOLFIRI (WJOG6210G)Naoki Izawa, Kohei Shitara, Kimio Yonesaka, et al.
Pageof 71

Showing results (591-600 of 709) with videos related to

Sort By:
Pageof 71
JCO Precision Oncology|January 20, 2022
<i>RAS</i> Mutations in Circulating Tumor DNA and Clinical Outcomes of Rechallenge Treatment With Anti-EGFR Antibodies in Patients With Metastatic Colorectal CancerYu Sunakawa, Masato Nakamura, Masahiro Ishizaki, et al.
Diagnostics (Basel, Switzerland)|April 3, 2021
Percutaneous Two-Dimensional Shear Wave Elastography for Diagnosis of Pancreatic TumorYotaro Iino, Hitoshi Maruyama, Rintaro Mikata, et al.
Cancer Medicine|July 28, 2018
A prospective Phase II study to examine the relationship between quality of life and adverse events of first-line chemotherapy plus cetuximab in patients with KRAS wild-type unresectable metastatic colorectal cancer: QUACK trialShigeyoshi Iwamoto, Akira Ooki, Satoshi Morita, et al.
ESMO Open|August 2, 2017
S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT studyHideo Baba, Yasuhide Yamada, Daisuke Takahari, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 13, 2012
Using chimeric mice with humanized livers to predict human drug metabolism and a drug-drug interactionToshihiko Nishimura, Toshiko Nishimura, Yajing Hu, et al.
ESMO Open|May 2, 2018
Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancerMasahito Kotaka, Takeharu Yamanaka, Takayuki Yoshino, et al.
Nature Communications|November 25, 2024
Modified FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: a randomized phase II DEEPER trialManabu Shiozawa, Yu Sunakawa, Takanori Watanabe, et al.
Scientific Reports|July 17, 2023
Estimation of the effect of atezolizumab plus bevacizumab on pulmonary arterial hypertension using computed tomography in HCC patientsTakayuki Kondo, Kisako Fujiwara, Miyuki Nakagawa, et al.
Liver Cancer|June 24, 2026
Disease Complexity and Nodule-Specific Responses to Atezolizumab plus Bevacizumab in Advanced Hepatocellular CarcinomaSae Yumita, Sadahisa Ogasawara, Makoto Fujiya, et al.
Targeted Oncology|September 22, 2020
Early Tumor Shrinkage and Depth of Response in the Second-Line Treatment for KRAS exon2 Wild-Type Metastatic Colorectal Cancer: An Exploratory Analysis of the Randomized Phase 2 Trial Comparing Panitumumab and Bevacizumab in Combination with FOLFIRI (WJOG6210G)Naoki Izawa, Kohei Shitara, Kimio Yonesaka, et al.
Pageof 71